Journal of developmental and behavioral pediatrics : JDBP · 2022
Buspirone for the Treatment of Generalized Anxiety Disorder in Down Syndrome: 3 Cases.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Howe Yamini J, Thom Robyn P, Notson Erin E, McDougle Christopher J, Palumbo Michelle L
Аннотация
OBJECTIVE: Reports on the pharmacologic treatment of anxiety, including generalized anxiety disorder (GAD), in individuals with Down syndrome (DS) are lacking.
METHODS: We present the case histories of 1 adolescent and 2 young adults with DS and the treatment course of comorbid GAD with buspirone.
RESULTS: Treatment with buspirone was safe and well-tolerated and resulted in sustained improvement in symptoms of anxiety for a minimum of 2 years in all 3 cases.
CONCLUSION: Buspirone's generally benign adverse effect profile makes it well suited for treating anxiety in individuals with DS in light of their common medical comorbidities.
METHODS: We present the case histories of 1 adolescent and 2 young adults with DS and the treatment course of comorbid GAD with buspirone.
RESULTS: Treatment with buspirone was safe and well-tolerated and resulted in sustained improvement in symptoms of anxiety for a minimum of 2 years in all 3 cases.
CONCLUSION: Buspirone's generally benign adverse effect profile makes it well suited for treating anxiety in individuals with DS in light of their common medical comorbidities.